PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1536.00 - 1565.00
1090.00 - 1784.00
46.2K / 155.6K (Avg.)
23.48 | 66.41
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-38.19%
Negative revenue growth while 5715.T stands at 2.17%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-26.78%
Negative gross profit growth while 5715.T is at 1.58%. Joel Greenblatt would examine cost competitiveness or demand decline.
-62.08%
Negative EBIT growth while 5715.T is at 21.48%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-81.50%
Negative operating income growth while 5715.T is at 8.89%. Joel Greenblatt would press for urgent turnaround measures.
-66.03%
Negative net income growth while 5715.T stands at 15.93%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-66.07%
Negative EPS growth while 5715.T is at 16.37%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-66.22%
Negative diluted EPS growth while 5715.T is at 16.44%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
0.03%
Slight or no buybacks while 5715.T is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
141.51%
10Y revenue/share CAGR above 1.5x 5715.T's 35.31%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
89.48%
5Y revenue/share CAGR above 1.5x 5715.T's 42.05%. David Dodd would look for consistent product or market expansions fueling outperformance.
20.00%
3Y revenue/share CAGR at 50-75% of 5715.T's 32.08%. Martin Whitman would question if the firm lags behind competitor innovations.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
127.76%
Below 50% of 5715.T's 18725.79%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
207.10%
5Y net income/share CAGR at 75-90% of 5715.T's 257.71%. Bill Ackman would advocate improvements to match competitor’s profit expansion.
130.41%
3Y net income/share CAGR above 1.5x 5715.T's 31.56%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
308.17%
10Y equity/share CAGR above 1.5x 5715.T's 124.43%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
53.44%
5Y equity/share CAGR above 1.5x 5715.T's 30.68%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
22.99%
3Y equity/share CAGR at 75-90% of 5715.T's 26.15%. Bill Ackman pushes for margin or operational changes to match the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9.10%
Firm’s AR is declining while 5715.T shows 3.01%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
9.51%
Inventory shrinking or stable vs. 5715.T's 36.66%. David Dodd confirms the company’s supply-chain is more efficient if sales are unaffected.
-2.40%
Negative asset growth while 5715.T invests at 8.57%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-0.44%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-3.42%
We’re deleveraging while 5715.T stands at 13.81%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-19.59%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-12.35%
We cut SG&A while 5715.T invests at 26.86%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.